Corvus Pharmaceuticals, Inc. (CRVS) Financials

CRVS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 253.2 million 12.5 million
Dec. 31, 2025 71.1 million 9.9 million
Sept. 30, 2025 80.5 million 8.7 million
June 30, 2025 89.5 million 9.2 million

CRVS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -10.5 million 2.7 million
Dec. 31, 2025 -9.2 million 1.6 million
Sept. 30, 2025 -9.6 million 1.2 million
June 30, 2025 -5.9 million 1.3 million

CRVS Net Income

No data available :(

CRVS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 236.7 million 406000 -
Dec. 31, 2025 56.8 million - 534000
Sept. 30, 2025 65.7 million - 1.0 million
June 30, 2025 74.4 million - 1.1 million

CRVS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 90.0 million
Dec. 31, 2025 79.7 million
Sept. 30, 2025 82.8 million
June 30, 2025 77.8 million

CRVS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 91000 11.2 million 3.7 million -
Dec. 31, 2025 25000 9.9 million 2.3 million -
Sept. 30, 2025 - 8.5 million 2.1 million -
June 30, 2025 113000 7.9 million 2.4 million -

CRVS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 29000
Dec. 31, 2025 - 26000
Sept. 30, 2025 - -
June 30, 2025 - 29000

CRVS

Price: $11.90

52 week price:
3.55
26.95

Earnings Per Share: -0.55 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 47000

Ebitda: -12.7 million

Market Capitalization: 940.1 million

Links: